

CRF Publications, Financial Year 2018-2019

1. Libertini M, Thway K, Noujaim J, et al. Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. *ANTICANCER RESEARCH*. 2018: 38(3) 1479-1483
2. Harvey H, Morgan V, Fromageau J, et al. Ultrasound Shear Wave Elastography of the Normal Prostate: Interobserver Reproducibility and Comparison with Functional Magnetic Resonance Tissue Characteristics. *ULTRASONIC IMAGING*. 2018: 40(3)158-170
3. Martins C D, Da Pieve C, Burley TA, et al. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. *CLINICAL CANCER RESEARCH*. 2018: 24(8)1853-1865
4. Libertini M, Mitra I, van der Graaf WTA, et al. Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. *CLINICAL SARCOMA RESEARCH*. 2018: 8 (3)
5. Hyer SL, Pratt B, Gray M, et al. Dosimetry-based treatment for Graves' disease. *NUCLEAR MEDICINE COMMUNICATIONS*. 2018: 39(6)486-492
6. Jerome NP, Boulton JKR, Orton MR, et al. Characterisation of fibrosis in chemically-induced rat mammary carcinomas using multi-modal endogenous contrast MRI on a 1.5T clinical platform. *EUROPEAN RADIOLOGY*. 2018: 28(4)1642-1653
7. Costa F, Doran S, Nill S, et al. Development of a methodology to study the effect of magnetic field on dose distributions in an MR-linac, using PRESAGE (R) and Monte Carlo calculations. *9TH INTERNATIONAL CONFERENCE ON 3D RADIATION DOSIMETRY Book Series: Journal of Physics Conference Series Volume: 847 Article Number: UNSP 012058 Published: 2017*
8. Khan K, Rata M, Cunningham D, et al. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. *GUT*: 2018 67(8) 1484-1492
9. Kousi E, O'Flynn EFM, Borri M, Morgan VA, DeSouza NM, Schmidt MA. Pre-treatment functional MRI of breast cancer: T2*evaluation at 3 T and relationship to dynamic contrast-enhanced and diffusion-weighted imaging. *MAGNETIC RESONANCE IMAGING*. 2018: 52 53-61
10. Manias KA, Harris LM, Davies NP, et al. Prospective multicentre evaluation and refinement of an analysis tool for magnetic resonance spectroscopy of childhood cerebellar tumours. *PEDIATRIC RADIOLOGY*: 2018 48(11) 1630-1641
11. Basu B, Krebs MG, Sundar R, et al. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. *ANNALS OF ONCOLOGY*. 2018: 29 (9) 1918-1925
12. Hunt A, Hansen VN, Oelfke U, et al. Adaptive Radiotherapy Enabled by MRI Guidance. *CLINICAL ONCOLOGY*. 2018: 30 (11) 711-719
13. O'Brien MER, Sarker D, Bhosle J, et al. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. *CANCER CHEMOTHERAPY AND PHARMACOLOGY*. 2018 82(5) 757-766.
14. Donners R, Blackledge M, Tunariu N, Messiou C, Merkle EM, Koh DM. Quantitative Whole-Body Diffusion-Weighted MR Imaging. *MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA* . 2018: 26(4)479-494

15. Reischauer C, Patzwahl R, Koh DM, Froehlich JM, Gutzeit A. Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases-A pilot study. EUR J RADIOL. 2018:101 184-190.
16. Messiou C, Kaiser M. Whole-Body Imaging in Multiple Myeloma. MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA. 2018: 26(4) 509-+
17. Menten MJ, Fast MF, Wetscherek A, et al. The impact of 2D cine MR imaging parameters on automated tumor and organ localization for MR-guided real-time adaptive radiotherapy. PHYSICS IN MEDICINE AND BIOLOGY. 2018 63(23) Article Number: 235005
18. deSouza NM, Tempny CM. A risk-based approach to identifying oligometastatic disease on imaging. INTERNATIONAL JOURNAL OF CANCER. 2019 144 (3) 422-430.
19. den Otter LA, Kaza E, Kierkels RGJ, et al. Reproducibility of the lung anatomy under active breathing coordinator control: Dosimetric consequences for scanned proton treatments. MEDICAL PHYSICS. 2018: 45 (12) 5525-5534.
20. Freedman JN, Collins DJ, Gurney-Champion OJ, et al. Super-resolution T2-weighted 4D MRI for image guided radiotherapy. RADIOTHERAPY AND ONCOLOGY . 2018: 129(3) 486-493
21. Arshad MA, Thornton A, Lu H, et al. Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. EUR J NUCL MED MOL IMAGING. 2019: 46, 455.
22. Dillon MT, Grove L, Newbold KL, et al. Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. CLINICAL CANCER RESEARCH. 2019: 25(2) 487-495.
23. Hunt A, Sohaib A, Serra M, et al. Multidisciplinary Inter-observer Variation using Magnetic Resonance Imaging (MRI) for Muscle Invasive Bladder Cancer (MIBC) Radiotherapy Target Definition. CLINICAL ONCOLOGY. 2019: 31 (2) E25-E26.
24. Evans TR, Jeffry DE, Molife LR, et al. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. BRITISH JOURNAL OF CANCER. 2019: 120 (4) 379-386.